

AMENDMENTS

Please amend the following claims:

Claim 1 (Currently amended) A pharmaceutical composition comprising:

a) a psychotropic, neurotropic or neurological drug, or an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug, wherein the drug is L-dopa, hydroxytryptamine, amantadine, benztropine, bromocryptine, diphenhydramine, levadopa, pergolid, trihexphenidyl, ethosuximide, valproic acid, carbamazepine, 10-hydroxycarbamazepine, 11-hydroxycarbamazepine, primidone, gabapentin, lamotrigine, felbamate, paramethadione, trimethadione, phenothiazine, thioxanthene, clozapine, haldoperidol, loxapine, a benzodiazapene antidepressants of the norepinephrine reuptake inhibitor type, a monoamine oxidase inhibitor, carotene, glutathione, N-acetylcysteine, methotrexate, azidothymidine, dideoxyinosine, dideoxycytosine, acyclovir, or gancyclovir;

b) ~~an amino acid or amino acid derivative specifically transported into a physiologically protected site, wherein the amino acid or derivative thereof is 5-hydroxytryptophan, serotonin, or melatonin; and~~

c) ~~a spacer having two linker functional groups and~~

d) ~~a spacer,~~

wherein the spacer has a first end and a second end and wherein the amino acid or amino acid derivative is attached to the first end of the spacer through a first linker functional group and the drug is attached to the second end of the spacer through a second linker functional group.

Claim 2 (cancelled)

Claim 3 (Currently amended). A pharmaceutical composition according to Claim 1 wherein the spacer allows the drug to act without being released at an intracellular site and wherein the first linker functional group attached to the first end of the spacer is strong and the second linker functional group attached to the second end of the spacer is weak.

Please
do not enter
this amendment
SAG
6/9/05